Trials / Completed
CompletedNCT02485873
Real-Life Evidence on Stroke Prevention in SPAF
REal-LIfe Evidence on Stroke Prevention in Patients With Atrial Fibrillation
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 8,607 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To obtain a better understanding on the comparative effectiveness of rivaroxaban and vitamin K antagonists (VKA) for stroke prevention in patients with non-valvular atrial fibrillation (SPAF) in a real-life setting
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rivaroxaban (Xarelto, BAY59-7939) | As prescribed by treating physicians |
| DRUG | Vitamin K antagonists | As prescribed by treating physicians |
Timeline
- Start date
- 2015-05-01
- Primary completion
- 2015-09-01
- Completion
- 2015-09-01
- First posted
- 2015-06-30
- Last updated
- 2015-11-11
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT02485873. Inclusion in this directory is not an endorsement.